BioPharma Resources

Drug Trial Radar · NCT05201781

A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel

Long-term Follow-up Study for Participants Previously Treated With Ciltacabtagene Autoleucel

Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

295

Planned (sponsor's estimate)

Start

Mar 9, 2022

Primary completion

Jul 29, 2037

Study completion Jun 30, 2041

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Jan 21, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to collect long-term follow-up data on delayed adverse events after administration of ciltacabtagene autoleucel (cilta-cel), and to characterize and understand the long-term safety profile of cilta-cel.

Conditions

  • Multiple Myeloma

Interventions

  • Cilta-celDrug

    Participants who had received cilta-cel in previous studies will be followed up in this study. No additional study treatment will be administered to participants in this study.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with New Malignancies and Recurrence of Pre-existing MalignancyTime frame: Up to 15 years
  2. Number of Participants with New Incidence or Exacerbation of a Pre-existing Neurologic DisorderTime frame: Up to 15 years
  3. Number of Participants with New Incidence or Exacerbation of a Pre-existing Rheumatologic or Other Autoimmune DisorderTime frame: Up to 15 years
  4. Number of Participants with New Incidence of Grade Greater than or Equal to (>=) 3 Hematologic Disorder Including HypogammaglobulinemiaTime frame: From year 1 up to year 5
  5. Number of Participants with Serious Hematologic Disorder, including HypogammaglobulinemiaTime frame: From year 6 up to year 15
  6. Number of Participants with New Incidence of Grade >= 3 InfectionTime frame: From year 1 up to year 5
  7. Number of Participants with Serious InfectionTime frame: From year 6 up to year 15
  8. Number of Participants with Serious Adverse Events (SAEs)Time frame: From year 1 up to year 5
  9. Number of Participants with Related Serious Adverse Events Assessed by the InvestigatorTime frame: From year 6 up to year 15

Locations

50 sites in 8 countries. Site status is shown where the registry gives one.

  • Mayo Clinic Cancer Center-Scottsdale

    Phoenix, Arizona · Recruiting

  • City of Hope

    Duarte, California · Recruiting

  • University of California San Francisco

    San Francisco, California · Recruiting

  • Stanford University Medical Center

    Stanford, California · Recruiting

  • Moffitt Cancer Center

    Tampa, Florida · Recruiting

  • Emory University

    Atlanta, Georgia · Recruiting

  • Northwestern University

    Chicago, Illinois · Recruiting

  • University of Chicago

    Chicago, Illinois · Recruiting

  • Indiana University

    Indianapolis, Indiana · Recruiting

  • Kansas University Medical Center

    Westwood, Kansas · Recruiting

  • Dana Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts · Recruiting

  • Massachusetts General Hospital

    Boston, Massachusetts · Recruiting

  • Barbara Ann Karmanos Cancer Institute

    Detroit, Michigan · Recruiting

  • Mayo Clinic Rochester

    Rochester, Minnesota · Recruiting

  • Washington University School Of Medicine

    St Louis, Missouri · Recruiting

  • Hackensack University Medical Center

    Hackensack, New Jersey · Recruiting

  • Rutgers Cancer Institute of New Jersey

    New Brunswick, New Jersey · Recruiting

  • Roswell Park Cancer Institute

    Buffalo, New York · Recruiting

  • Mount Sinai Medical Center

    New York, New York · Recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Recruiting

  • Montefiore Medical Center

    The Bronx, New York · Recruiting

  • Levine Cancer Institute

    Charlotte, North Carolina · Recruiting

  • University of Pennsylvania

    Philadelphia, Pennsylvania · Recruiting

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania · Recruiting

  • Sarah Cannon Research Institute

    Nashville, Tennessee · Recruiting

  • MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • Froedtert Memorial

    Milwaukee, Wisconsin · Recruiting

  • UZ Gent

    Ghent, Belgium · Recruiting

  • UZ Leuven

    Leuven, Belgium · Recruiting

  • Peking University Third Hospital

    Beijing, China · Active not recruiting

  • West China Hospital Si Chuan University

    Chengdu, China · Active not recruiting

  • Fujian Medical University Union Hospital

    Fuzhou, China · Active not recruiting

  • Sun Yat-sen University Cancer Hospital

    Guangzhou, China · Active not recruiting

  • First Hospital, Zhejiang University Medical College

    Hangzhou, China · Active not recruiting

  • Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School

    Nanjing, China · Active not recruiting

  • Jiangsu Province Hospital

    Nanjing, China · Active not recruiting

  • Shanghai Changzheng Hospital

    Shanghai, China · Active not recruiting

  • Ruijin Hospital Shanghai Jiao Tong University

    Shanghai, China · Active not recruiting

  • Shanghai Fourth People s Hospital

    Shanghai, China · Active not recruiting

Showing 40 of 50 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.